Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease

NCT07496021 is registered in ClinicalTrials.gov with CKD Bio Corporation as lead sponsor.

NCT NCT07496021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07496021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, 24-Week Proof-of-Concept Study to Evaluate the Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's Disease
Lead sponsor
CKD Bio Corporation
Phase
Not applicable
Overall status
Recruiting
Start date
February 23, 2026
Completion date
May 31, 2027
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

early alzheimers disease